Condition
Metastatic Chondrosarcoma
Total Trials
5
Recruiting
1
Active
2
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
200%
2 of 1 completed with results
Key Signals
2 with results50% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 1 (1)
P 2 (3)
Trial Status
Terminated1
Withdrawn1
Recruiting1
Active Not Recruiting1
Completed1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06176989Phase 2RecruitingPrimary
Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
NCT01267955Phase 2Active Not Recruiting
Vismodegib in Treating Patients With Advanced Chondrosarcomas
NCT03670069Phase 1Terminated
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
NCT01330966Phase 2Completed
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
NCT04098887Not ApplicableWithdrawnPrimary
Lattice Stereotactic Body Radiation Therapy (Lattice SBRT) for Localized Unresectable or Metastatic Conventional Type Chondrosarcoma
Showing all 5 trials